Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Recruiting · NCT06421675 · Registry updated 2026-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Shock, Systemic Inflammatory Response Syndrome, cardiovascular disorder, cytokine release syndrome, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-09-28 | NCT06421675 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| McMaster University | 202 |
| Ontario Clinical Oncology Group (OCOG) | 9 |
| Pfizer | 431 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BC Cancer - Victoria | Victoria | Canada | 4 |
| Juravinski Cancer Center | Hamilton | Canada | 1 |
| Kingston General Hospital | Kingston | Canada | 12 |
| London Health Science Centre - Victoria Hospital | London | Canada | 1 |
| Ottawa Hospital | Ottawa | Canada | 10 |
| Vancouver Cancer Center | Vancouver | Canada | 1 |